Th17 cells and IL-17 A-Focus on immunopathogenesis and immunotherapeutics

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 2, 2013, Pages 158-170

  Van Den Berg, Wim B ^a   McInnes, Iain B ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Brodalumab; Interleukin 17; Ixekizumab; Secukinumab; Th17 cells

Indexed keywords

BRIAKINUMAB; BRODALUMAB; ETANERCEPT; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 22; INTERLEUKIN 7; IXEKIZUMAB; PLACEBO; SECUKINUMAB; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; ARTICLE; ASTHMA; AUTOIMMUNITY; BACKACHE; CD4+ T LYMPHOCYTE; CYTOKINE PRODUCTION; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; ENTERITIS; GASTROINTESTINAL DISEASE; HEADACHE; HOST RESISTANCE; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INFECTION; INHIBITION KINETICS; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INTESTINE FLORA; LEUKOPENIA; LYMPHOCYTE DIFFERENTIATION; MULTIPLE SCLEROSIS; NONHUMAN; PAIN; PHARYNGITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RHINITIS; RHINOPHARYNGITIS; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; TH17 CELL; TREATMENT INDICATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTIGO;

BRODALUMAB; INTERLEUKIN-17; IXEKIZUMAB; SECUKINUMAB; TH17 CELLS;

ARTHRITIS, RHEUMATOID; CYTOKINES; HUMANS; INTERLEUKIN-17; PSORIASIS; TH17 CELLS;

EID: 84886067284     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.04.006     Document Type: Article

References (157)

1. O'Connor W. Jr, Zenewicz L.A., Flavell R.A. The dual nature of TH17 cells: shifting the focus to function. Nat Immunol 2010;11:471-476.
2. Brennan F.M., McInnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008, 118:3537-3545.
3. Miossec P., Korn T., Kuchroo V.K. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009, 361:888-898.
4. Zhu S., Qian Y. IL-17/IL-17 receptor system in autoimmune disease: mechanisms and therapeutics. Clin Sci 2012, 122:487-511.
5. Ivanov S., Lindén A. Interleukin-17 as a drug target in human disease. Trends Pharmacol Sci 2009, 30:95-103.
6. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone: I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986, 136:2348-2357.
7. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005, 201:233-240.
8. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
9. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
10. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu Rev Immunol 2009, 27:485-517.
11. Zhang L., Yuan S., Cheng G., Guo B. Type I IFN promotes IL-10 production from T cells to suppress Th17 cells and Th17-associated autoimmune inflammation. PLoS ONE 2011, 6:e28432.
12. + T cells. Arthritis Res Ther 2009, 11:257.
13. H17 cells in gastrointestinal diseases. Mediators Inflamm 2009, 2009:132028. [Epub 2010 Feb 8].
14. Ichiyama K., Yoshida H., Wakabayashi Y., Chinen T., Saeki K., Nakaya M., et al. Foxp3 inhibits RORγt-mediated IL-17A mRNA transcription through direct interaction with RORγt. J Biol Chem 2008, 283:17003-17008.
15. + regulatory T cells of psoriasis patients easily differentiate into IL-17A-producing cells and are found in lesional skin. J Invest Dermatol 2011, 131:1853-1860.
16. Macpherson A.J., Harris N.L. Interactions between commensal intestinal bacteria and the immune system. Nat Rev Immunol 2004, 4:478-485.
17. Atarashi K., Tanoue T., Umesaki Y., Honda K. Regulation of Th17 cell differentiation by intestinal commensal bacteria. Benef Microbes 2010, 1:327-334.
18. Ivanov I.I., Atarashi K., Manel N., Brodie E.L., Shima T., Karaoz U., et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 2009, 139:485-498.
19. Klaasen H.L.B.M., Koopman J.P., van den Brink M.E., Bakker M.H., Poelma F.G.J., Beynen A.C. Intestinal, segmented, filamentous bacteria in a wide range of vertebrate species. Lab Anim 1993, 27:141-150.
20. Reading N.C., Kasper D.L. The starting lineup: key microbial players in intestinal immunity and homeostasis. Front Microbiol 2011, 2:148.
21. Ivanov I.I., Littman D.R. Segmented filamentous bacteria take the stage. Mucosal Immunol 2010, 3:209-212.
22. Abdollahi-Roodsaz S., Joosten L.A.B., Koenders M.I., Devesa I., Roelofs M.F., Radstake T.R.D.J., et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 2008, 118:205-216.
23. Wu H.J., Ivanov I.I., Darce J., Hattori K., Shima T., Umesaki Y., et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010, 32:815-827.
24. Abdollahi-Roodsaz S., Joosten L.A., Roelofs M.F., Radstake T.R., Matera G., Popa C., et al. Inhibition of toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 2007, 56:2957-2967.
25. Cua D.J., Tato C.M. Innate IL-17-producin cells: the sentinels of the immune system. Nat Rev Immunol 2010, 10:49-89.
26. Rouvier E., Luciani M.F., Mattéi M.G., Denizot F., Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J Immunol 1993, 150:5445-5456.
27. Yao Z., Painter S.L., Fanslow W.C., Ulrich D., Macduff B.M., Spriggs M.K., et al. Human IL-17: a novel cytokine derived from T cells. J Immunol 1995, 155:5483-5486.
28. Gaffen S.L. Structure and signaling in the IL-17 receptor family. Nat Rev Immunol 2009, 9:556-567.
29. Pappu R., Ramirez-Carrozzi V., Ota N., Ouyang W., Hu Y. The IL-17 family cytokines in immunity and disease. J Clin Invest 2010, 30:185-195.
30. Chang S.H., Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses. Cell Res 2007, 17:435-440.
31. + T cells. J Biol Chem 2007, 282:13447-13455.
32. Kramer J.M., Yi L., Shen F., Maitra A., Jiao X., Jin T., et al. Evidence for ligand-independent multimerization of the IL-17 receptor. J Immunol 2006, 176:711-715.
33. Ho A.W., Shen F., Conti H.R., Patel N., Childs E.E., Peterson A.C., et al. IL-17RC is required for immune signaling via an extended SEF/IL-17R signaling domain in the cytoplasmic tail. J Immunol 2010, 185:1063-1070.
34. Chang S.H., Park H., Dong C. Act1 adaptor protein is an intermediate and essential signaling component of interleukin-17 receptor. J Biol Chem 2006, 281:35603-35607.
35. Qian Y., Liu C., Hartupee J., Altuntas C.Z., Gulen M.F., Jane-Wit D., et al. The adaptor Act1 is required for interleukin 17-dependent signaling associated with autoimmune and inflammatory disease. Nat Immunol 2007, 8:247-256.
36. Hartupee J., Liu C., Novotny M., Li X., Hamilton T. IL-17 enhances chemokine gene expression through mRNA stabilization. J Immunol 2007, 179:4135-4141.
37. Ruddy M.J., Wong G.C., Liu X.K., Yamamoto H., Kasayama S., Kirkwood K.L., et al. Functional cooperation between interleukin-17 and tumor necrosis factor-α is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem 2004, 279:2559-2567.
38. Shen F., Hu Z., Goswami J., Gaffen S.L. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J Biol Chem 2006, 281:24138-24148.
39. Shen F., Li N., Gade P., Kalvakolanu D.V., Weibley T., Doble B., et al. IL-17 receptor signaling inhibits C/EBPβ by sequential phosphorylation of the regulatory 2 domain. Sci Signal 2009, 2(59):ra8.
40. Maitra A., Shen F., Hanel W., Mossman K., Tocker J., Swart D., et al. Distinct functional motifs within the IL-17 receptor regulate signal transduction and target gene expression. Proc Natl Acad Sci USA 2007, 104:7506-7511.
41. Henness S., van Thoor E., Ge Q., Armour C.L., Hughes J.M., Ammit A.J. IL-17A acts via p38 MAPK to increase stability of TNF-α-induced IL-8 mRNA in human ASM. Am J Physiol Lung Cell Mol Physiol 2006, 290:L1283-L1290.
42. Hot A., Zrioual S., Toh M.L., Lenief V., Miossec P. IL-17A- versus IL-17F-induced intracellular signal transduction pathways and modulation by IL-17RA and IL-17RC RNA interference in rheumatoid synoviocytes. Ann Rheum Dis 2011, 70:341-348.
43. Iwakura Y., Nakae S., Saijo S., Ishigame H. The roles of IL-17A in inflammatory immune responses and host defense against pathogens. Immunol Rev 2008, 226:57-79.
44. Onishi R.M., Gaffen S.L. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010, 129:311-321.
45. Ishigame H., Kakuta S., Nagai T., Kadoki M., Nambu A., Komiyama Y., et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity 2009, 30:108-119.
46. Homey B., Dieu-Nosjean M.C., Wiesenborn A., Massacrier C., Pin J.J., Oldham E., et al. Up-regulation of macrophage inflammatory protein-3α/CCL-20 and CC chemokine receptor 6 in psoriasis. J Immunol 2000, 164:6621-6632.
47. Nograles K.E., Zaba L.C., Guttman-Yassky E., Fuentes-Duculan J., Suárez-Fariñas M., Cardinale I., et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008, 159:1092-1102.
48. Harper E.G., Guo C., Rizzo H., Lillis J.V., Kurtz S.E., Skorcheva I., et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol 2009, 129:2175-2183.
49. Liang S.C., Tan X.Y., Luxenberg D.P., Karim R., Dunussi-Joannopoulos K., Collins M., et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006, 203:2271-2279.
50. Gutowska-Owsiak D., Schaupp A.L., Salimi M., Selvakumar T.A., McPherson T., Taylor S., et al. IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol 2012, 21:104-110.
51. Shi X., Jin L., Dang E., Chang T., Feng Z., Liu Y., et al. IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms. J Invest Dermatol 2011, 131:2401-2408.
52. Hvid H., Teige I., Kvist P.H., Svensson L., Kemp K. TPA induction leads to a Th17-like response in transgenic K14/VEGF mice: a novel in vivo screening model of psoriasis. Int Immunol 2008, 20:1097-1106.
53. van der Fits L., Mourits S., Voerman J.S.A., Kant M., Boon L., Laman J.D., et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol 2009, 182:5836-5845.
54. H17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007, 445:648-651.
55. Ma H.L., Liang S., Li J., Napierata L., Brown T., Benoit S., et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008, 118:597-607.
56. Lin A.M., Rubin C.J., Khandpur R., Wang J.Y., Riblett M., Yalavarthi S., et al. Mast cells and neutrophils release IL-17 through extracellular trap formation in psoriasis. J Immunol 2011, 187:490-500.
57. + T cell trafficking and development by IFN-γ: mechanism and pathological relevance in psoriasis. J Immunol 2008, 181:4733-4741.
58. Ziolkowska M., Koc A., Luszczykiewicz G., Ksiezopolska-Pietrzak K., Klimczak E., Chwalinska-Sadowska H., et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporine A-sensitive mechanism. J Immunol 2000, 164:2832-2838.
59. Metawi S.A., Abbas D., Kamal M.M., Ibrahim M.K. Serum and synovial fluid levels of interleukin-17 in correlation with disease activity in patients with RA. Clin Rheumatol 2011, 30:1201-1207.
60. Suurmond J., Dorjée A.L., Boon M.R., Knol E.F., Huizinga T.W.J., Toes R.E.M., et al. Mast cells are the main interleukin 17-positive cells in anticitrullinated protein antibody-positive and -negative rheumatoid arthritis and osteoarthritis synovium. Arthritis Res Ther 2011, 13:R150.
61. Chabaud M., Durand J.M., Buchs N., Fossiez F., Page G., Frappart L., et al. Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum 1999, 42:963-970.
62. Hwang S.Y., Kim J.Y., Kim K.W., Park M.K., Moon Y., Kim W.U., et al. IL-17 induces production of IL-6 and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-κB- and PI3-kinase/Akt-dependent pathways. Arthritis Res Ther 2004, 6:R120-R128.
63. Shahrara S., Pickens S.R., Dorfleutner A., Pope R.M. IL-17 induces monocyte migration in rheumatoid arthritis. J Immunol 2009, 182:3884-3891.
64. Shahrara S., Pickens S.R., Mandelin A.M., Karpus W.J., Huang Q., Kolls J.K., et al. IL-17-mediated monocyte migration occurs partially through CC chemokine ligand 2/monocyte chemoattractant protein-1 induction. J Immunol 2010, 184:4479-4487.
65. Chabaud M., Garnero P., Dayer J.M., Guerne P.A., Fossiez F., Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000, 12:1092-1099.
66. van Bezooijen R.L., van der Wee-Pals L., Papapoulos S.E., Löwik C.W.G.M. Interleukin 17 synergises with tumour necrosis factor α to induce cartilage destruction in vitro. Ann Rheum Dis 2002, 61:870-876.
67. Koenders M.I., Joosten L.A.B., van den Berg W.B. Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis. Ann Rheum Dis 2006, 65(SUPPL. 3):iii29-iii33.
68. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673-2682.
69. Adamopoulos I.E., Chao C.C., Geissler R., Laface D., Blumenschein W., Iwakura Y., et al. Interleukin-17A upregulates receptor activator of NF-κB on osteoclast precursors. Arthritis Res Ther 2010, 12:R29.
70. Lubberts E., Joosten L., Oppers B., van den Bersselaar L., Coenen-de Roo C., Kolls J., et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol 2001, 167:1004-1013.
71. Koenders M.I., Marijnissen R.J., Devesa I., Lubberts E., Joosten L.A.B., Roth J., et al. Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: rationale for combination treatment during arthritis. Arthritis Rheum 2011, 63:2329-2339.
72. Koenders M.I., Lubberts E., Oppers-Walgreen B., van den Bersselaar L., Helsen M.M., Di Padova F.E., et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol 2005, 167:141-149.
73. Abdollahi-Roodsaz S., Joosten L.A., Helsen M.M., Walgreen B., van Lent P.L., van den Bersselaar L.A., et al. Shift from toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production. Arthritis Rheum 2008, 58:3753-3764.
74. Koenders M.I., Marijnissen R.J., Joosten L.A., Abdollahi-Roodsaz S., Di Padova F.E., van de Loo F.A., et al. T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 neutralization. Arthritis Rheum 2012, 64:1762-1770.
75. Baxter D., McInnes I.B., Kurowska-Stolarska M. Novel regulatory mechanisms in inflammatory arthritis: a role for microRNA. Immunol Cell Biol 2012, 90:288-292.
76. Stanczyk J., Pedrioli D.M., Brentano F., Sanchez-Pernaute O., Kolling C., Gay R.E., et al. Altered expression of microRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum 2008, 58:1001-1009.
77. Stanczyk J., Ospelt C., Karouzakis E., Filer A., Raza K., Kolling C., et al. Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum 2011, 63:373-381.
78. Kurowska-Stolarska M., Alivernini S., Ballantine L.E., Asquith D.L., Millar N.L., Gilchrist D.S., et al. MicroRNA-155 as a proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci USA 2011, 108:11193-11198.
79. Blüml S., Bonelli M., Niederreiter B., Puchner A., Mayr G., Hayer S., et al. Essential role of microRNA-155 in the pathogenesis of autoimmune arthritis in mice. Arthritis Rheum 2011, 63:1281-1288.
80. Zhu S., Pan W., Song X., Liu Y., Shao X., Tang Y., et al. The microRNA miR-23b suppresses IL-17-associated autoimmune inflammation by targeting Table2, Table3 and IKK-α. Nat Med 2012, 18:1077-1086.
81. Niimoto T., Nakasa T., Ishikawa M., Okuhara A., Izumi B., Deie M., et al. MicroRNA-146a expresses in interleukin-17 producing T cells in rheumatoid arthritis patients. BMC Musculoskelet Disord 2010, 11:209.
82. Nakasa T., Shibuya H., Nagata Y., Niimoto T., Ochi M. The inhibitory effect of microRNA-146a expression on bone destruction in collagen-induced arthritis. Arthritis Rheum 2011, 63:1582-1590.
83. Raychaudhuri S.P. Role of IL-17 in psoriasis and psoriatic arthritis. Clin Rev Allergy Immunol 2012, [Epub ahead of print, accessed 24 Feb 2012].
84. Zepp J., Wu L., Li X. IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating disease. Trends Immunol 2011, 32:232-239.
85. Wang Y.H., Wills-Karp M. The potential role of interleukin-17 in severe asthma. Curr Allergy Asthma Rep 2011, 11:388-394.
86. Noordenbos T., Yeremenko N., Gofita I., van de Sande M., Tak P.P., Caňete J.D., et al. Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis. Arthritis Rheum 2012, 64:99-109.
87. + cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 2011, 13:R95.
88. Moran E.M., Mullan R., McCormick J., Connolly M., Sullivan O., FitzGerald O., et al. Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biological therapies. Arthritis Res Ther 2009, 11:R113.
89. Chiricozzi A., Guttman-Yassky E., Suárez-Fariñas M., Nograles K.E., Tian S., Cardinale I., et al. Integrative responses to IL-17 and TNF-α in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 2011, 131:677-687.
90. Granet C., Miossec P. Combination of the pro-inflammatory cytokines IL-1, TNF-α, and IL-17 leads to enhanced expression and additional recruitment of AP-1 family members, Egr-1, and NF-κB in osteoblast-like cells. Cytokine 2004, 26:169-177.
91. Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000, 13:715-725.
92. Presky D.H., Yang H., Minetti L.J., Chua A.O., Nabavi N., Wu C.Y., et al. A functional interleukin 12 complex is composed of two β-type cytokine receptor subunits. Proc Natl Acad Sci USA 1996, 93:14002-14007.
93. Parham C., Chirica M., Timans J., Vaisberg E., Travis M., Cheung J., et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rβ1 and a novel cytokine receptor subunit, IL-23R. J Immunol 2002, 168:5699-5708.
94. Luger D., Silver P.B., Tang J., Cua D., Chen Z., Iwakura Y., et al. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J Exp Med 2008, 205:799-810.
95. Damsker J.M., Hansen A.M., Caspi R.R. Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci 2010, 1183:211-221.
96. Germann T., Szeliga J., Hess H., Störkel S., Podlaski F.J., Gately M.K., et al. Administration of interleukin 12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc Natl Acad Sci USA 1995, 92:4823-4827.
97. Murphy C.A., Langrish C.L., Chen Y., Blumenschein W., McClanahan T., Kastelein R.A., et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J Exp Med 2003, 198:1951-1957.
98. Teunissen M.B., Koomen C.W., de Waal Malefyt R., Wierenga E.A., Bos J.D. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998, 111:645-649.
99. Li J., Shen W., Kong K., Liu Z. Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis. Scand J Immunol 2006, 64:515-522.
100. Andersson A.K., Feldmann M., Brennan F.M. Neutralizing IL-21 and IL-15 inhibits pro-inflammatory cytokine production in rheumatoid arthritis. Scand J Immunol 2008, 68:103-111.
101. Young D.A., Hegen M., Ma H.L.M., Whitters M.J., Albert L.M., Lowe L., et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007, 56:1152-1163.
102. - T cell expansion is essential for the development of arthritis in autoimmune K/BxN mice. J Immunol 2009, 182:4649-4656.
103. Witte E., Witte K., Warszawska K., Sabat R., Wolk K. Interleukin-22: a cytokine produced by T, NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev 2010, 21:365-379.
104. Marijnissen R.J., Koenders M.I., Smeets R.L., Stappers M.H., Nickerson-Nutter C., Joosten L.A.B., et al. Increased expression of interleukin-22 by synovial Th17 cells during late stages of murine experimental arthritis is controlled by interleukin-1 and enhances bone degradation. Arthritis Rheum 2011, 63:2939-2948.
105. Geboes L., Dumoutier L., Keichtermans H., Schurgers E., Mitera T., Renauld J.C., et al. Proinflammatory role of the Th17 cytokine interleukin-22 in collagen-induced arthritis in C57BL/6 mice. Arthritis Rheum 2009, 60:390-395.
106. Sarkar S., Zhou X., Justa S., Bommireddy S.R. IL-22 reduces the severity of collagen arthritis in association with increased levels of IL-10. Arthritis Rheum 2013, 10.1002/art.37849.
107. Kim K.W., Kim H.R., Park J.Y., Park J.S., Oh H.J., Woo Y.J., et al. Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. Arthritis Rheum 2012, 64:1015-1023.
108. Leipe J., Schramm M.A., Grunke M., Baeuerle M., Dechant C., Nigg A.P., et al. Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis. Ann Rheum Dis 2011, 70:1453-1457.
109. - entheseal resident T cells. Nat Med 2012, 18:1069-1076.
110. Sonnenberg G.F., Nair M.G., Kirn T.J., Zaph C., Fouser L.A., Artis D. Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A. J Exp Med 2010, 207:1293-1305.
111. van Roon J.A.G., Glaudemans K.A.F.M., Bijlsma J.W.J., Lafeber F.P.J.G. Interleukin 7 stimulates tumour necrosis factor α and Th1 cytokine production in joints of patients with rheumatoid arthritis. Ann Rheum Dis 2003, 62:113-119.
112. + T cells and macrophages. Arthritis Rheum 2005, 52:1700-1710.
113. Hartgring S.A.Y., Bijlsma J.W.J., Lafeber F.P.J.G., van Roon J.A.G. Interleukin-7 induced immunopathology in arthritis. Ann Rheum Dis 2006, 65(SUPPL. 3):iii69-iii74.
114. Hartgring S.A.Y., Willis C.R., Alcorn D., Nelson L.J., Bijlsma J.W.J., Lafeber F.P.J.G., et al. Blockade of the interleukin-7 receptor inhibits collagen-induced arthritis and is associated with reduction of T cell activity and proinflammatory mediators. Arthritis Rheum 2010, 62:2716-2725.
115. McInnes I.B., Gracie J.A. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004, 4:392-397.
116. McInnes I.B., al-Mughales J., Field M., Leung B.P., Huang F.P., Dixon R., et al. The role of interleukin-15 in T-cell migration and activation in rheumatoid arthritis. Nat Med 1996, 2:175-182.
117. McInnes I.B., Leung B.P., Sturrock R.D., Field M., Liew F.Y. Interleukin-15 mediates T cell-dependent regulation of tumor necrosis factor-α production in rheumatoid arthritis. Nat Med 1997, 3:189-195.
118. Hoeve M.A., Savage N.D., de Boer T., Langenberg D.M., de Waal Malefyt R., Ottenhoff T.H., et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 2006, 36:661-670.
119. Halvorsen E.H., Strønen E., Hammer H.B., Goll G.L., Sollid L.M., Molberg Ø. Interleukin-15 induces interleukin-17 production by synovial T cell lines from patients with rheumatoid arthritis. Scand J Immunol 2011, 73:243-249.
120. + T cell response to produce IL-17. Eur J Immunol 2007, 37:2744-2752.
121. Ferrari-Lacraz S., Zanelli E., Neuberg M., Donskoy E., Kim Y.S., Zheng X.X., et al. Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis. J Immunol 2004, 173:5818-5826.
122. Nakae S., Komiyama Y., Nambu A., Sudo K., Iwase M., Homma I., et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002, 17:375-387.
123. Nakae S., Nambu A., Sudo K., Iwakura Y. Suppression of immune induction of collagen-induced arthritis in IL-17-deficient mice. J Immunol 2003, 171:6173-6177.
124. Yang X.O., Chang S.H., Park H., Nurieva R., Shah B., Acero L., et al. Regulation of inflammatory responses by IL-17F. J Exp Med 2008, 205:1063-1075.
125. Bush K.A., Farmer K.M., Walker J.S., Kirkham B.W. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum 2002, 46:802-805.
126. Lubberts E., Koenders M.I., Oppers-Walgreen B., van den Bersselaar L., Coenen-de Roo C.J.J., Joosten L.A.B., et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:650-659.
127. Chao C.C., Chen S.J., Adamopoulos I.E., Davis N., Hong K., Vu A., et al. Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 2011, 44:243-252.
128. Ishiguro A., Akiyama T., Adachi H., Inoue J., Nakamura Y. Therapeutic potential of anti-interleukin-17A aptamer; suppression of interleukin-17A signaling and attenuation of autoimmunity in two mouse models. Arthritis Rheum 2011, 63:455-466.
129. + γδ T cells, drive arthritic bone destruction in mice and humans. J Immunol 2011, 186:2602-2612.
130. + regulatory T cells involving CTLA4 signaling in a psoriasis-like skin disorder. J Immunol 2010, 184:7257-7267.
131. Nakajima K., Kanda T., Takaishi M., Shiga T., Miyoshi K., Nakajima H., et al. Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model. J Immunol 2011, 186:4481-4489.
132. Rizzo H.L., Kagami S., Phillips K.G., Kurtz S.E., Jacques S.L., Blauvelt A. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 2011, 186:1495-1502.
133. Cai Y., Shen X., Ding C., Qi C., Li K., Li X., et al. Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation. Immunity 2011, 35:596-610.
134. McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, et al. The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 2009;10:314-324.
135. Ratsimandresy R.A., Duvallet E., Assier E., Semerano L., Delavallée L., Bessis L., et al. Active immunization against IL-23p19 improves experimental arthritis. Vaccine 2011, 29:9329-9336.
136. Yago T., Nanke Y., Kawamoto M., Furuya T., Kobashigawa T., Kamatani N., et al. IL-23 induces human osteoclastogenesis via IL-17 in vitro, and anti-IL-23 antibody attenuates collagen-induced arthritis in rats. Arthritis Rheum 2007, 9:R96.
137. Hueber W., Patel D.D., Dryja T., Wright A.M., Koroleva I., Bruin G., et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med 2010, 2:52ra72.
138. Genovese M.C., Van den Bosch F., Roberson S.A., Bojin S., Biagini I.M., Ryan P., et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum 2010, 62:929-939.
139. Papp K., Leonardi C., Menter A., Ortonne J.P., Krueger J.G., Kricorian G., et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012, 366:1181-1189.
140. Papp K.A., Langley R.G., Sigurgeirsson B., Abe M., Baker D.R., Konno P., et al. Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a randomised, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013, 168(2):412-421.
141. Rich P., Sigurgeirsson B., Thaci D.P., Ortonne J.P., Paul C., Schopf R.E., et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol 2013, 168(2):402-411.
142. Leonardi C., Matheson R., Zachariae C., Cameron G., Li L., Edson-Heredia E., et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012, 366:1190-1199.
143. Genovese M.C., Durez P., Richards H.B., Supronik J., Dokoupilova E., Mazurov V., et al. Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 2012, 10.1136/annrheumdis-2012-201601.
144. Genovese M., Kellner H., Durez P., Codding C., Logozio G., Richards H., et al. Secukinumab treatment improves ACR50, HAQ-DI and EULAR remission rates in patients with rheumatoid arthritis. Ann Rheum Dis 2012, 71(SUPPL. 3):191. [abstract].
145. Genovese M.C., Greenwald M.W., Cho C.S., Berman A., Jin L., Cameron G., et al. A phase 2 study of multiple subcutaneous doses of LY2439821, an anti-IL-17 monoclonal antibody, in patients with rheumatoid arthritis in two populations: naïve to biologic therapy or inadequate responders to tumor necrosis factor alpha inhibitors. Arthritis Rheum 2011, 63(SUPPL. 10):S1017. [abstract].
146. McInnes I., Sieper J., Braun J., et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomized, double-blind, placebo-controlled, phase 2 proof-of-concept trial. Ann Rheum Dis 2013, [Epub ahead of print].
147. Baraliakos X., Braun J., Laurent D.D., Baeten D., van der Heijde D., Sieper J., et al. Interleukin-17A blockade with secukinumab reduces spinal inflammation in patients with ankylosing spondylitis as early as week 6, as detected by magnetic resonance imaging. Arthritis Rheum 2011, 63(SUPPL. 10):S972. [abstract].
148. Leonardi C.L., Kimball A.B., Papp K.A., Yeilding N., Guzzo C., Wang Y., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008, 371:1665-1674.
149. Papp K.A., Langley R.G., Lebowl M., Krueger G.G., Szapary P., Yeilding N., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008, 371:1675-1684.
150. Griffiths C.E., Strober B.E., van de Kerkhop P., Ho V., Fidelus-Gort R., Yeilding N., et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010, 362:118-128.
151. Strober B.E., Crowley J.J., Yamauchi P.S., Olds M., Williams D.A. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011, 165:661-668.
152. Gordon K.B., Langley R.G., Gottlieb A.B., Papp K.A., Kreuger G.G., Strober B.E., et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012, 132:304-314.
153. Reich K., Langley R.G., Papp K.A., Ortonne J.P., Unnebrink K., Kaul M., et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011, 365:1586-1596.
154. Gottlieb A., Menter A., Mendelsohn A., Shen Y.K., Li S., Guzzo C., et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009, 373:633-640.
155. Kavanaugh A., McInnes I.B., Gottlieb A.B., Puig L., Rahman P., Ritchlin C.T., et al. Ustekinumab in patients with active psoriatic arthritis: results of the phase 3, multicenter, double-blind, placebo-controlled Psummit I study. Arthritis Rheum 2012, 64(SUPPL. 10):S1083-S1084. [abstract].
156. Ritchlin C.T., Gottlieb A.B., McInnes I.B., Puig L., Rahman P., Li S., et al. Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: results of a phase 3, multicenter, double-blind, placebo-controlled study. Arthritis Rheum 2012, 64(SUPPL. 10):S1080-S1081. [abstract].
157. Puel A., Cypowyj S., Bustamante J., Wright J.F., Liu L., Lim H.K., et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011, 332:65-68.